Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(BSNS WIRE) Q Television Network Inks an Agreement with America West Airlines
Q Television Network Inks an Agreement with America West Airlines
Business Editors / Airline Writers / Entertainment Editors
PALM SPRINGS, Calif.--(BUSINESS WIRE)--March 9, 2005--
Q Television Network (Pink Sheets: QBID), announced
today that America West Airlines has signed a marketing agreement with
Q Television Network.
This agreement allows Q Television the right to link itself to
America West Airline's gay and lesbian promotions page at
www.americawest.com/glbt, where Q Television will be promoted.
"We are very excited to begin a marketing relationship with
America West," said Frank Olsen, President and CEO of Q Television.
"They are one of the many new companies Q Television has reached
agreements with and we look forward to adding more valuable partners
in the future."
About America West: Approximately 55,000 customers upgrade their
low-fare experience every day when they get on board America West. The
airline's 13,000 employees are proud to offer a range of services
including more destinations than any other low-cost carrier,
first-class cabins, assigned seating, airport clubs and an
award-winning frequent flyer program. America West operates
approximately 900 flights daily to 95 destinations in the U.S.,
Canada, Mexico and Costa Rica. This press release and additional
information on America West can be accessed at www.americawest.com.
About Q Television Network: This television network was organized
to create and develop a network devoted to providing television
programming for the gay and lesbian community. While the company
expects much of its subscriber base to be comprised of members of the
gay and lesbian population, management also believes that quality
programming about the gay and lesbian experience, designed to
entertain, educate and inform, will attract many other segments of the
viewing public. The company's programming will be available on a
subscription basis to those desiring its programming. The network will
broadcast 24 hours per day, 7 days per week. Providing distribution
via satellite ensures availability of the network across the United
States, including Alaska, Hawaii and Puerto Rico. For further
information on programming and subscriptions, please visit
www.qtelevision.com.
Safe Harbor Statement
As a cautionary note to investors, certain matters discussed in
this press release may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
matters involve risks and uncertainties that may cause actual results
to differ materially, including the following: changes in economic
conditions; general competitive factors; the television network's
ability to execute its business model and strategic plans; and the
risks described from time to time in the company's Securities and
Exchange Commission filings.
KEYWORD: NORTH AMERICA ARIZONA CALIFORNIA UNITED STATES
INDUSTRY KEYWORD: ENTERTAINMENT TV AND RADIO TRANSPORT AIR CONSUMER GAY & LE
BIAN CONTRACT/AGREEMENT
SOURCE: Q Television Network
CONTACT INFORMATION:
CWR & Partners, LLP
Ronnie Welch, 508-222-4802
Ronnie@cwrpartners.com
*** end of story ***
In that article they did get it wrong.http://www.investorshub.com./boards/read_msg.asp?message_id=5656113 For more information and audio samples from her CDs, try Mahan's website at www.steffmahan.com
You can find out more information on the Q Television Network at www.qtelevisionnetwork.com
For more information about the Steff Mahan segment on the Q Television Network, check out www.herounit.com
Here is a good picture of Nick Oram http://www.qtelevision.com/images/nickoram1.jpg
Here is a good picture of Nick Oram http://www.qtelevision.com/images/nickoram1.jpg
Yes, saw him yesterday. Had a few drinks to celebrate.
My friend, Terry Fountain, just got nominated yesterday for his second Emmy on "Ellen" , he won last year.
Jennifer Love Hewitt is on "Ellen" right now. 3:30 PST
(PR NEWSWIRE) DNAPrint genomics Introduces New Product for Law Enforcement
DNAPrint genomics Introduces New Product for Law Enforcement
SARASOTA, Fla., Feb. 23 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC Bulletin Board: DNAP) today announced the introduction of its new
DNAWitness(TM) testing kit utilizing the Company's proprietary DNAWitness(TM)
forensics technology for the law enforcement market, the only testing method
available with predictive capability that can identify the percentage of a
person's genetic makeup.
"The kit is a natural progression of the Company's DNAWitness(TM) testing
service, which previously was only performed at DNAPrint's Sarasota
laboratory, and will enable forensics experts to conduct their own tests in
their own facilities," stated Richard Gabriel, the Company's President and
Chief Executive Officer. "We anticipate that by making DNAWitness(TM)
directly available to law enforcement agencies, the kit will lead to more
rapid integration of our technology into the global forensics market and we
expect it to be a significant revenue source for the Company. At the same
time, we will continue to build on our established DNAWitness(TM) custom
services at our own facilities to clients who prefer to outsource their DNA
laboratory work."
DNAWitness(TM) forensics technology analyzes DNA recovered at a crime
scene and provides the percentage of Bio-Geographical Ancestry (BGA) makeup
among four possible genetic groups -- Sub-Saharan Africa, Native American,
East Asian and Indo-European, narrowing the list of potential suspects that
investigators are seeking in connection with a crime.
"The kit puts the power of DNAPrint's forensics technology directly into
the hands of local crime scene investigators," stated Zach Gaskin, DNAPrint's
Technical Coordinator of Forensics. "It also is a valuable time- and cost-
saving investigative tool because it reduces the number of false leads that
detectives normally would have to chase. In addition, many forensics
laboratories want to keep control of their crime scene samples in order to
maintain a chain of custody for evidence in order to reduce challenges in
court."
The kit, officially introduced on Tuesday at the American Academy of
Forensic Science meeting in New Orleans, La., is the first of its kind
developed for the consumable test kit market and contains all of the reagents
and protocols required for forensics laboratories around the world to perform
their own ancestry analysis. Proprietary on-line software systems provided by
DNAPrint(TM) are expected to enable investigators to interpret their results
and relate them to the likely anthropometric (physical) features of a would-be
suspect by referencing DNA samples to DNAPrint's proprietary ancestry
databases.
The DNAWitness(TM) kit can be utilized on capillary electrophoresis (CE)
instruments commonly found in forensic and university laboratories. Starting
this week, the kit will be entering beta testing at select forensics
laboratories. After the testing phase, which is expected to take three to
four months, the Company intends to build an inventory of kits for its
distributor network and its own sales force for sale to the forensics market.
The Company's testing services are available for the screening of a large
number of samples or individual samples, until and even after the kit is
available; investigators, forensic scientists and medical examiners need not
wait until the kit is available to access this powerful new technology.
DNAPrint(TM) introduced DNAWitness(TM) technology to the law enforcement
community in early 2003 and immediately gained national attention when it was
credited with assisting in the apprehension of a suspected serial killer in
Louisiana. It currently is aiding law enforcement agencies in more than 80
criminal investigations in the United States, United Kingdom, Australia and
Canada.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company's ANCESTRYby DNA(TM)
is a consumer product for individuals interested in learning their family
heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA
evidence recovered at a crime scene. DNAPrint is also developing products in
the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic
tool that matches ovarian cancer patients with the most suitable form and dose
of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to
determine whether patients will be good or poor responders to statins, which
are effective in cholesterol reduction. For more information about the
company, please visit http://www.dnaprint.com .
Safe Harbor Provision
All statements in this press release that are not historical are forward-
looking statements that are subject to risks and uncertainties that could
cause actual results to differ materially from those projected, including, but
not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation.
DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DNAPrint's expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based.
Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
SOURCE DNAPrint genomics
Contact Information:
Richard Gabriel, President and CEO, DNAPrint genomics, +1-941-366-3400; or Ron S
abiner, The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics
WebSite:
http://www.dnaprint.com/
*** end of story ***
Ant was on The Last Comic Standing on NBC last year http://www.imdb.com/name/nm0030714/
Samuel Jackson's movie "Coach Carter" is still in the top 5 movies and he was the main guest.
Saw it Friday 1/28 at 11:35pm in Los Angeles. It was our repeat.
Did you read the link to the ad?http://www.print2webcorp.com/marketplace/sarasota/main/ViewPage.aspx?fn=1&en=296582&pg=29737...
******I want my Q Television Sign-up List....
UPDATED LIST: 9:37am
If you want Q Television please put your cable or Satellite carrier along with where you live. We will send this list to QBID after we have a good number of people on the list.....
1)firefight4- Cablevision NY
2)PBandJ- Directv Ft. Myers, FL
3) FOXY - Comcast,Toms River New Jersey
4)Robertmic71 - Directv, Long Island NY
5) BigT - Cablevision, Stamford, CT / Directv
6) lilpennypincher- Cablevision, Sussex Co. NJ
7) realityinc21-Insight Communications, Bloomington, Indiana
8) CHIMAN34 - Comcast, Addison Illinois
9)Matrixxx- West Palm Beach, FL, DirecTV
10)kosmomtx - Dishnetwork, Dallas, TX
11}BBSTOCK - COMCAST.ATLANTA ,GEORGIA
12)econnelle - Dish Network, Green Oak, MI
13)Dinger51 - Time Warner Cable - Cleveland, OH
14)nealgalt - Sierra Vista, AZ Directv
15)lobogotti - Indianapolis, Indiana
16) willbur- comcast, chicago IL
17) BillH- Direct TV, Sherman Oaks, CA
Tyler the webhost is on Q chat now and looking for webcam people
Listening now, with no problems
I am listening, no problems here.
skunksyard,I get one of their fruitcakes every Christmas from Joe Don Baker. Just got one yesterday. The best fruitcake ever.
This is his website http://www.glinn.com/. Seems we have a reformed basher.
Good news from an old basher. http://ragingbull.lycos.com/mboard/boards.cgi?board=QBID&read=677235
Some real news.
I have not posted here for a long time as there is no real discussion here, just insults and nonsense. TMM and its activities have always made it appear to be nothing but a stock scam. Many of its news releases were false. However, I have to give credit when it is due.
It does look like they are actually serious this time about getting their network launched. This is not to say it will be successful, but it does appear to finally be an honest and meaningful attempt.
The real news is that, although I had my suspicions at first, the contract with the Gay Games is for real and TMM has made "two substantial cash payments" to the Games as called for by the contract.
I have reported plenty of bad news about this company, so I thought it was only fair to report this bit of good news.
(Voluntary Disclosure: Position- No Position)
(COMTEX) B: Q Television Network Retires One Billion Shares
B: Q Television Network Retires One Billion Shares
PALM SPRINGS, Calif., Dec 14, 2004 (BUSINESS WIRE) -- Q Television Network,
(Pink Sheets: QBID) announced today that its CEO, Mr. Frank Olsen, will retire
1,000,000,000 shares of his personal QBID stock.
Q Television's board of directors has agreed to retire the QBID shares to the
treasury. The 1,000,000,000 shares are QBID common stock. Mr. Olsen will retain
voting rights and a long term conversion provision. The retirement of the stock
will occur in pre-set blocks over the next two months.
"This non-dilutive measure will bring an increased value to our shareholders,"
said Olsen. "We have negotiated and put contracts into place to ensure longevity
for our network and, as this occurs, we will take steps to bring value to our
shareholders."
About Q Television Network
This television network was organized to create and develop a network devoted to
providing television programming for the gay and lesbian community. While the
company expects much of its subscriber base to be comprised of members of the
gay and lesbian population, management also believes that quality programming
about the gay and lesbian experience, designed to entertain, educate and inform,
will attract many other segments of the viewing public. The company's
programming will be available on a subscription basis to those desiring its
programming. The network will broadcast 24 hours per day, 7 days per week.
Providing distribution via satellite ensures availability of the network across
the United States, including Alaska, Hawaii and Puerto Rico. For further
information on programming and subscriptions, please visit www.qtelevision.com.
Safe Harbor Statement
As a cautionary note to investors, certain matters discussed in this press
release may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such matters involve risks and
uncertainties that may cause actual results to differ materially, including the
following: changes in economic conditions; general competitive factors; the
television network's ability to execute its business model and strategic plans;
and the risks described from time to time in the company's Securities and
Exchange Commission filings.
SOURCE: Q Television Network
CONTACT: CWR & Partners, LLP
Ronnie Welch, 508-222-4802
Ronnie@cwrpartners.com
Copyright (C) 2004 Business Wire. All rights reserved.
-0-
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: TELEVISION/RADIO
CABLE
ADVERTISING/MARKETING
CONSUMER/HOUSEHOLD
BOND/STOCK
RATINGS
Copyright
Business
Wire
2004
*** end of story ***
FAQ is working too!
Thanksgiving Day
November 25† †
Christmas
December 24**
† † The Exchange will close at 1 p.m. ET on Friday, November 26, 2004 (the day after Thanksgiving).
http://www.nyse.com/Frameset.html?displayPage=/about/1022963613686.html
Microsoft Corporation EQUITY, OFFICERS & ADDRESS Page 5 of 10
Common Stock $.00025 Par, 9/04, 24B auth., 10,865,000,000
issd. Insiders own 14% (incl. 30.4M options). IPO 3/86,
2.8M shs. @ $21 by Goldman, Sachs & Co. 6/92, 6/91, 3-for-2
stock splits; 2/03, 3/99, 2/98, 12/96, 5/94, 4/90, 9/87,
2-for-1 stock splits. *4/01, Company acquired Great Plains
Software @ 1.1 shares (22,248,761 shares issd.).
No, doesnt look active
This guy?? are you sure it is not a she? His/her other aliases are:
yellow_kryptonite
phill_n_deblanks
temper_temper_now
baby_hueys_diapers
take_my_temp
measles_on_my_mind
sans_a_belt_porky
side-saddle_sal
wholly_owned_front
webbed_toe_wilbur
corn_in_my_stool
cyclops_pig_on_i-v
sux_2b_a_stuck
urinary_plumber
acromegaly_and_corn
q-tips_4_beginners
acne_and_rubber-skin
3_legs_and_2_teeth
300mg_raid_per_hr
swirl-top_comb-over
scabie the clown
step_right_up0
pee_wee_peter
trick_knee
father_mcgillicuddy
bongo_butter
count_lugwig
cmore_the_jungleboy
dont_touch_that_dial
the_fcc
i_was_gaay
matta_network
wacl-cal
wheres_the_gap
gapper_or_crapper
standard_fruit
gap_or_crap
504_paper_route
toxic_pigtails
weeble_fall_down
prom_queen_toxins
q-tips_for_beginners
decubitus_anti_serum
siamese_twin_w_aids
carnie_dental-care
greasy_kid_stuff
perianal_gravy-train
mc_saturated_phats
7_fingers-23_toes
skin_like_rubber
the_pennycon_project
27_toes_and_no_corns
pink-eye_the_cyclops
pock-mark_kid
3_doublejointed_toes
the_co-mingle_jingle
nocarb_ketone_capone
(PR NEWSWIRE) Biofrontera Strengthens Its Dermatology Drug Pipeline By Acquirin
a Phase II Compound
Biofrontera Strengthens Its Dermatology Drug Pipeline By Acquiring a Phase II Co
pound
LEVERKUSEN, Germany, Oct. 7 /PRNewswire/ -- Biofrontera AG today announced
that it has acquired from ASAT AG, Zug, Switzerland all intellectual property,
know-how and material related to a phase II compound for the treatment of
various cancerous and precancerous skin lesions and some gynecological
indications. The product applies aminolevulinic acid (ALA) in a patented
nanocolloid formulation, ideally suited for photodynamic therapy (PDT). PDT is
a novel and effective approach for the treatment of basal cell carcinomas and
actinic keratosis.
With two dermatology products in advanced clinical development, both with
an anticipated market introduction in 2007 or 2008, Biofrontera considers
itself ideally positioned for building a specialty pharma business in the
field of dermatology.
The novel nanocolloid formulation of ALA provides effective permeation of
the compound specifically into the malignant tissue and enhances the formation
of protoporphyrine in these cells, ultimately causing cell degeneration.
Efficacy and safety of the new formulation have been investigated with
positive results in pilot phase II and phase III studies. Biofrontera came to
the conclusion that the new formulation has some clear advantages over similar
existing therapies, allowing the application of much lower doses of the active
substance at the same efficacy. Following successful completion of clinical
development, the first entry to the market is expected in 2007. The
transaction was coordinated and managed by InterPharmaLink AG, Basel,
Switzerland.
Prof. Dr. Lubbert, CEO of Biofrontera AG, commented: "We are delighted to
have acquired this extremely promising product in photodynamic therapy, a
fairly novel treatment paradigm. The nanocolloid formulation of ALA ideally
suits the dermatology focus of our leading products and combines the benefits
of an already existing therapy with an innovative, in all likelihood superior
formulation. Similar to our other dermatological clinical development
compound, we consider the development risk of this product extremely low. This
makes us very confident that we will be able to bring this new product to the
market."
About Biofrontera AG
Biofrontera is aiming to become a specialty pharma business, initially in
the field of dermatology, with internal research capacity to extend its drug
pipeline. Major shareholders of Biofrontera include Heidelberg Innovation and
the 3i group. DNAPrint genomics Inc., a genomics-based company based in
Sarasota, FL, recently also agreed to acquire a significant stake in
Biofrontera.
http://www.biofrontera.com
About InterPharmaLink
InterPharmaLink is a professional healthcare management consulting firm.
The emphasis is on initiating and managing business transactions in the areas
of late-stage development projects, in-market products and business
development for the pharmaceutical industry.
SOURCE Biofrontera AG
-0- 10/07/2004
/CONTACT: Anke zur Muhlen, Corporate Communication, Biofronters AG,
+011-49-0-214-87632-22, or +011-49-0-214-87632-90; or Richard Gabriel, CEO and
President, DNAPrint(TM) genomics, Inc., +1-941-366-3400/
/Web site: http://www.biofrontera.com /
(DNAP)
CO: Biofrontera AG
ST: Germany
IN: HEA MTC OTC
SU:
*** end of story ***
I didnt't come over from anywhere. I have been on IHUB since day one. I have read many boards since 2000. I don't need to see my name in print or post 24/7. I was curious to why you have to post so much on a stock that I own, and you don't. Friends were asking the same. See you on the other side !!! !
Obsessed, hmmm I have 3 posts on this board. You have ??????
You post for the attention that generates your cult following and nothing more. I see people like you everyday, you love your name in print!!! You could care less about anybody but yourself and your twisted agenda. Save the world, Save the world, Save the world on and on infinitum!!!!!!!!!!!!!!!!!!!!!!!!!!!. I have people come here for a little info and you just hog the space. Say it once and get over it. You are not going to change anything!!!. If you want your own platform , get your own board and go crazy!!!!! Damn, you are one egocentric,starchasing,lonely, woman!!!!!!!!!! Just for you, janiceshell,janiceshell,janiceshell,janiceshell,janiceshell,janiceshell,janiceshell!!! There, don't post for 10 minutes, I got your name covered in print.
Since this is the "Janice Shell" board, why does the header say CMKM-CMKM Diamonds Inc. Somebody should change the header to JSHELL or JANICESHELL. I tell people to check out the CMKX board on IHUB, and all they see is Janice Shell, Janice Shell, Janice Shell>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>Damn,looks like Raging Bull all over. Confusion reigns!!!!!!!!!!!!!
Yesterdays News (PR NEWSWIRE) DNAPrint Announces the Release of RETINOME(TM) for the Forensic M
rket: Eye Color Prediction From Crime Scene DNA!
DNAPrint Announces the Release of RETINOME(TM) for the Forensic Market: Eye Colo
Prediction From Crime Scene DNA!
SARASOTA, Fla., Aug. 17 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
announced today that it has finished validating an ultra-high throughput
version of its proprietary RETINOME(TM) genetic test for predicting human
(eye) iris color from DNA. The new test has been added to the Company's
proprietary DNAWitness(TM) 2.5 physical profiling package of genome tests sold
to forensics and security investigators.
The completion of the RETINOME(TM) project and the addition of the new
RETINOME(TM) product to the Company's DNAWitness(TM) package of genome tests
constitute a dramatic advance in the newly developing science of molecular
forensics profiling, where the goal is to paint a physical profile from crime
scene DNA.
RETINOME(TM) provides an accurate inference of iris (eye) color from the
measurement of proprietary single nucleotide polymorphisms (SNPs) distributed
throughout the human genome. The genetic basis of this trait has vexed
geneticists for decades. As detailed in an article published in a recent
'Trends in Genetics' review article, RETINOME(TM) was developed from a genome
screen of tens of thousands of genome SNPs in thousands of European subjects.
A necessary but not sufficient component of the RETINOME(TM) technology was
first published by DNAPrint(TM) scientists last spring in the peer-reviewed
journal, "Genetics." Since the discovery of the genetic keys for predicting
iris color from DNA 3 years ago, the Company has been augmenting, evaluating
and optimizing the performance of its innovative RETINOME(TM) genome test.
The most recent blind validation test for 65 individuals of predominant (>80%)
European ancestry, between the ages of 10 and 60 years, showed greater than
97% accuracy. A "blind" test is one in which a model is used to classify a
trait for samples that were not used to develop the model in any way, and
provides an indication of the generality of the model for field application.
DNAPrint's computer scientists developed innovative and proprietary software
that proved to be the key to unlocking the door to this difficult trait.
"As a presumptive test designed for investigative, rather than human
identity applications which suggest culpability, a 97% accuracy rate
corresponds to a solid 'A' grade," said Zach Gaskin. "The test is appropriate
for samples that have typed with the Company's DNAWitness(TM) 2.5 test to be
of predominant European continental ancestry, and was blindly validated
strictly for individuals of both sexes between the ages of 10 and 60 years."
The validation and commercial implementation of RETINOME(TM) using this
powerful approach is a historic event; RETINOME(TM) becomes the first test
developed and validated for the inference of a complex genetics trait from
DNA. Prior to the human genome era, complex genetics traits such as disease
proclivity, drug response and particularly physical traits such as iris and
hair color vexed geneticists for decades. The excitement generated by the
completion of the human genome sequence draft in 2001 was based on the hope
that common human traits would finally be understood from a genetics
perspective. The ultimate expression of genetic understanding is demonstrated
by showing an ability to predict or infer a trait from DNA sequences, but so
far this hope has remained largely unfulfilled. Prior to RETINOME(TM), no
predictive genome-based test had been developed, described in the peer-
reviewed literature or, most importantly, launched commercially. DNAPrint's
ability to do so stems from its innovative approach for screening the human
genome that feeds from the mathematical fuel provided by natural human
population structure. "We are very proud to be the first to demonstrate how
the promise of the human genome project can be fulfilled in a practical
sense," said Tony Frudakis, DNAPrint's Chief Scientific Officer.
"DNAPrint's success with this difficult trait has profound implications
for its goal of developing a pipeline of small molecule drugs that target
specific human subpopulations," said Richard Gabriel, CEO and President.
"More immediately, a grant is available from the National Institutes of
Justice and can be found at: http://www.ojp.usdoj.gov/nij/funding.htm and is
specific for 'Solving Cold Cases with DNA.' Now not only can we tell the
genetic profile of the crime scene DNA, but we can also describe the eye color
if their DNA genetic results fall into the correct category. Each time we do
this, we are reducing the "donor pool" of individuals and the number of
suspects. Combining our DNAWitness(TM) technology with RETINOME(TM) and
standard STR testing, as well as mitochondrial and y-Chromosome testing, this
is a powerful combination of information for the investigators. Our photo
database system of images, coupled with an eye color prediction, are just the
beginning of our forensic products for the investigative community. We intend
to aggressively roll out additional services over the next several years to
enhance the predictive ability of our Company's products and services from
crime scene DNA."
RETINOME(TM) is available today along with DNAWitness(TM) and can be
ordered directly from any of the following companies: DNAPrint genomics, Inc.
http://www.dnaprint.com ; ReliaGene Technologies, Inc.
http://www.reliagene.com and Lynn Peavey Company http://www.lynnpeavey.com .
About ReliaGene Technologies, Inc.
Founded in 1990 and based in the New Orleans, LA metro area, ReliaGene
Technologies Inc. is a leading DNA laboratory facility specializing in human
genetic identification and related bio-tech product development. With
cutting-edge capabilities for forensic and paternity DNA testing, ReliaGene
has now successfully detected human genetic profiles from over 400,000
biological samples, including cases from all 50 U.S. states and over 35
countries worldwide. ReliaGene's Y-PLEX(TM) genotyping systems, first
released in 2000, are now sold in over 40 countries with market demand
increasing steadily. DNAWitness is available through ReliaGene and for more
information, please visit: http://www.reliagene.com.
About Lynn Peavey Company
Lynn Peavey is the leader in providing law enforcement with forensic
innovations for use at the crime scene and in the laboratory. Lynn Peavey
reaches over 17,000 law enforcement agencies, medical examiners and crime
laboratories across the country. The Lynn Peavey Company has an on-line
catalog and bound catalog by request for all crime scene materials and
including a DNAWitness testing kit. For more information, please visit:
http://www.lynnpeavey.com
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
Ancestrybydna in the consumer market and DNAWitness in the forensic market in
2003. DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the NASDAQ OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit: http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 08/17/2004
/CONTACT: Richard Gabriel, CEO/President, DNAPrint Genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com
http://www.reliagene.com
http://www.lynnpeavey.com /
(DNAP)
CO: DNAPrint genomics, Inc.; ReliaGene Technologies, Inc.; Lynn Peavey
Company
ST: Florida
IN: MTC OTC
SU: PDT
*** end of story ***